FindTrial
Sign In

Efficacy and safety of TJ-54 (Yokukansan) for post-operative delirium, psychiatric symptoms, and pain: systematic review and meta-analysis.

Efficacy and safety of TJ-54 (Yokukansan) for post-operative delirium, psychiatric symptoms, and pain: systematic review and meta-analysis. - Efficacy and safety of TJ-54 (Yokukansan) for post-operative delirium, psychiatric symptoms, and pain: systematic review and meta-analysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050029
Enrollment
Unknown
Registered
2023-01-13
Start date
2023-01-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative patients treated with TJ-54 (Yokukansan)

Interventions

None listed

Sponsors

Okayamasaiseikai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PICO Patients: post-operative patients Intervention: use of TJ-54 (Yokukansan) Comparison: no use of TJ-54 (Yokukansan) or placebo Outcome: post-operative delirium, psychiatric symptoms, and pain

Exclusion criteria

Exclusion criteria: Trials with different target drugs Trials without outcome assessment

Design outcomes

Primary

MeasureTime frame
the efficacy of TJ-54(Yokukansan) for post-operative delirium, psychiatric symptoms, and pain—

Secondary

MeasureTime frame
the safety of TJ-54(Yokukansan) for post-operative delirium, psychiatric symptoms, and pain—

Countries

Japan

Contacts

Public ContactKazumasa Kotake

Okayamasaiseikai General Hospital Department of pharmacy

kottanketty@gmail.com086-252-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026